China's Covid-19 vaccine candidate shows some promise in animal tests

While no Covid-19 vaccine has been approved for sale yet, more than 150 are in development globally with an aim to help end the pandemic

Animal tests of a potential Covid-19 vaccine being developed by Chinese researchers show it triggers an immune response against the novel coronavirus, offering some promise as it goes into early-stage human trials, according to a peer-reviewed study.

ARCoV is a messenger RNA vaccine which uses technology similar to candidates being developed by Moderna and BioNtech and Pfizer. It is the second potential Covid-19 vaccine that China's military-backed research unit has moved into clinical trials.

Results of trials of ARCoV in mice and monkeys, published in the peer-reviewed medical journal Cell on Thursday, show both single and two-dose inoculations induced strong antibody and T-cell responses against several Covid-19-causing virus strains.

However, researchers conducting the trial cautioned they were not yet able to see how long the ARCoV-induced antibodies might last or how strong their protection might be to other strains that cause Covid-19 but were not tested in the study.

ARCoV is stable at 25°C (77°F) for at least a week, researchers said, which could make it more attractive for potential immunisation campaigns in hard-to-reach populations in places where cold-chain storage and transportation are not always reliable.

While no Covid-19 vaccine has been approved for sale yet, more than 150 are in development globally with an aim to help end the global pandemic that has claimed over 600,000 lives. But whether any will succeed remains far from clear.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel